Alrizomadlin

DB17549InvestigationalSmall molecule

Alrizomadlin is a novel MDM2 inhibitor that blocks the interaction of MDM2 and p53. It is being investigated in cancers.

Formula / weight: C₃₄H₃₈Cl₂FN₃O₄ · 642.59 g/mol (avg)
Also known as: (3'r,4's,5'r)-4-((6-chloro-2-oxo-1,2-dihydro-spiro(indole-3,3'-pyrrolidin)e-4'-(3-chloro-2-fluoro -phenyl)-1'-ethyl-spiro(cyclohexane-1,2'-pyrrolidine)-5'-carbonyl)-amino)-bicyclo(2.2.2)octane-1-carboxylic acid · 4-((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamido)bicyclo [2.2.2]octane-1-carboxylic acid · Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'r,4's,5'r)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3h)indol)-5'-yl)carbonyl)amino)-
Code names: AA-115 · APG-115

Resolves to

Compound

UNII15QAU0SI9JCAS1818393-16-6ChEMBLCHEMBL4091801

Structure

InChIKeyYJCZPJQGFSSFOL-MNZPCBJKSA-NSMILESCCN1[C@H]([C@H](C2=CC=CC(Cl)=C2F)[C@]2(C(=O)NC3=CC(Cl)=CC=C23)C11CCCCC1)C(=O)NC12CCC(CC1)(CC2)C(O)=O

Targets

P04637TP53Q00987MDM2

What you can answer from here — as of April 23, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Alrizomadlin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account